Want to see JP:4582 full AI Analyst Report?
Symbio Pharmaceuticals Limited (4582) AI Stock Analysis
Symbio Pharmaceuticals Limited
(TSE/TYO:4582)
The stock scores at the absolute minimum of 37, reflecting a confluence of severe risks. The most significant factor is the company's precarious financial state, marked by collapsing revenues, massive cash burn, and a leveraged balance sheet that raises going-concern doubts. This is compounded by a bearish technical trend with the price below all major moving averages and deeply negative momentum. The negative P/E and absent dividend offer no valuation support. The company faces an existential crisis without a dramatic operational turnaround.
Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 2.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 668.42K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.82
- Revenue Growth
- -30.58%
- EPS Growth
- 6.93%
- Country
- Japan
- Employees
- 91
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Symbio Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers...
Symbio Pharmaceuticals Limited Financial Statement Overview
Summary
Financial health is critically weak. Revenue collapsed 87% over three years to ¥1.3B, net losses are massive (-¥4.8B), and operating cash flow is deeply negative (-¥4.6B). A new ¥2.0B debt load has created a high 1.56 debt-to-equity ratio, while equity has eroded to ¥1.3B. The company is burning cash rapidly, posing a severe going-concern risk.
Income Statement
10Very NegativeBalance Sheet
15Very NegativeCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13B | 1.31B | 2.45B | 5.59B | 10.01B | 8.25B |
| Gross Profit | 791.92M | 947.34M | 1.87B | 4.41B | 7.60B | 5.80B |
| EBITDA | -5.99B | -4.60B | -3.78B | -714.00M | 2.06B | 1.11B |
| Net Income | -6.03B | -4.78B | -3.83B | -1.96B | 1.18B | 2.03B |
Balance Sheet | ||||||
| Total Assets | 1.91B | 3.87B | 4.97B | 8.17B | 17.43B | 15.18B |
| Cash, Cash Equivalents and Short-Term Investments | 977.18M | 2.88B | 3.96B | 6.52B | 6.28B | 3.86B |
| Total Debt | 832.50M | 1.98B | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.49B | 2.60B | 770.77M | 8.14B | 8.92B | 8.43B |
| Stockholders Equity | -582.85M | 1.27B | 4.20B | 7.21B | 8.51B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -4.58B | -3.44B | -427.48M | 1.57B | 76.20M |
| Operating Cash Flow | 0 | -4.58B | -3.42B | -194.69M | 1.61B | 140.04M |
| Investing Cash Flow | 0 | -75.92M | -3.96M | -376.70M | -47.13M | -70.85M |
| Financing Cash Flow | 0 | 3.62B | 708.47M | 680.16M | 627.99M | -71.92M |
Symbio Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 43.00 is below the 20-day moving average (MA) of 50.15, below the 50-day MA of 55.82, and below the 200-day MA of 82.14, indicating a bearish trend. The MACD of -3.40 indicates Positive momentum. The RSI at 20.32 is Positive, neither overbought nor oversold. The STOCH value of 8.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.
Symbio Pharmaceuticals Limited Peers Comparison
Overall Rating
JP:457461Neutral
JP:459751.75Neutral
JP:453946.5Neutral
JP:451245Neutral
JP:458637Underperform- JP:458237Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4574 | 61Neutral | JPY 13.02B | 19.21 | ― | 1.25% | 13.30% | 66.38% |
| JP:4597 | 52Neutral | JPY 7.37B | -7.81 | -53.67% | ― | 32.42% | 61.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4539 | 47Neutral | JPY 5.47B | -11.34 | ― | 3.35% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 10.52B | 30.43 | ― | 1.17% | 25.89% | ― |
| JP:4586 | 37Underperform | JPY 3.29B | -2.95 | ― | ― | 167.44% | 49.38% |
| JP:4582 | 37Underperform | JPY 3.72B | -0.47 | ― | ― | -30.58% | 6.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4582 | Symbio Pharmaceuticals Limited | 43.00 | -72.00 | -62.61% | |
| JP:4597 | Solasia Pharma KK | 26.00 | -7.00 | -21.21% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 300.00 | 12.42 | 4.32% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1494.00 | 9.29 | 0.63% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 263.00 | -12.00 | -4.36% | |
| JP:4586 | Medrx Co., Ltd. | 42.00 | -87.00 | -67.44% |
Symbio Pharmaceuticals Limited Corporate Events
SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026
SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales dropping 25.6% year-on-year to ¥722 million and losses deepening as operating profit fell to a ¥4,870 million...
SymBio’s First-Half Loss Deepens as Equity Turns Negative
SymBio Pharmaceuticals reported a sharp decline in first-half 2026 net sales to ¥469 million, down 27.3% year on year, alongside a wider operating loss of ¥3.64 billion as the company remained in a loss-making phase. The firm’s financ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026